|Articles|October 1, 2004

Preventive Medicine in Managed Care - Comprehensive Adrenergic Blockade: Improving Outcomes Across t
Volume 10
Issue 1 Prevent

Safety and Statins: Pharmacologic and Clinical Perspectives

Download PDF: Safety and Statins: Pharmacologic and Clinical Perspectives

Articles in this issue

almost 22 years ago

Article

Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines?

almost 22 years ago

Article

Neurohormones and the Progression of Cardiovascular Disease: What's Behind High Risk?

almost 22 years ago

Article

Role of Neurohormonal Antagonists in Management of Patients With Hypertension, Metabolic Syndrome, and Diabetes

almost 22 years ago

Article

Participating Faculty

almost 22 years ago

Article

CME Quiz

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

Safety and Statins: Pharmacologic and Clinical Perspectives

Articles in this issue

Related Content

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

Trending on AJMC

FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance

Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog

Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MD

PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women

CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited